Close

Improving the lives of patients by combating metastatic cancer

We create innovative tools that provide deeper insights into cancer behaviour

The Vortex mission is to be the innovation leader in CTC capture technology that improves therapeutic decisions and saves lives

A New Window into Cancer Biology

Circulating tumour cells (CTCs) provide a real-time window into cancer biology; offering critical insights into the molecular and cellular mechanisms that drive the disease.

There is a major shift toward liquid biopsy in how cancer is studied and treated. As an innovation leader in Circulating Tumour Cell (CTC) capture technology, we’re helping researchers isolate and study circulating tumour cells — a key step in developing the next generation of anti-metastatic cancer therapies. Our advanced system offers a powerful tool to support more targeted and effective treatment development.

Circulating Tumour Cells Offer a Key Advantage

Circulating tumour cells (CTCs) provide real time insights into tumours progression. The analysis of CTCs can help to guide treatment decisions and improve patient outcomes.

Unlike circulating tumour DNA (ctDNA), CTCs are intact, viable cancer cells that provide real-time insights into tumour progression, evolution and treatment resistance. Their ability to deliver both molecular and functional information makes them invaluable for precision oncology.

VTX-1 Liquid Biopsy System

The Vortex VTX-1 Liquid Biopsy System simplifies and automates the isolation and collection of clinically relevant, viable CTCs directly from whole blood.

qui1000_female_doctcor_mixed_race_smiling_talking_to_patient_in_056944c5-0357-40c3-88f6-a089196ed4e0

Vortex Biosciences Pioneers Live CTC Capture for Personalised Cancer Care

https://www.proactiveinvestors.co.uk/companies/news/994522/netscientific-portfolio-company-vortex-ceo-says-pharma-and-biotech-to-drive-next-stage-of-growth-994522.html London, UK – October
Read More
Screenshot 2025-06-12 at 12.47.48

Paul Jones Appointed CEO of Vortex Biotech Holdings

London, UK – August 16, 2022 – Vortex Biotech Holdings, a leading oncology liquid biopsy company and a portfolio company of NetScientific PLC, today announced the appointment of Pau
Read More
qui1000_Upward_trending_graphs_or_charts_with_a_clean_modern_de_2f10cf02-750b-4dca-9382-1abb76ca57f2

NetScientific Reacquires Significant Stake in Vortex Biotech Holdings

https://www.proactiveinvestors.co.uk/companies/news/981579/netscientific-acquiring-30-stake-in-materially-de-risked-vortex-biotech-981579.html London, UK – May 6, 2022 – NetScientif
Read More